<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30348261</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>26</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>26</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1769-6917</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>105</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Bulletin du cancer</Title>                <ISOAbbreviation>Bull Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>[Early phase trials at the &quot;Institut de cancérologie de l'Ouest&quot;: Clinical outcome and validation of prognostic scores].</ArticleTitle>            <Pagination>                <MedlinePgn>896-906</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0007-4551(18)30189-9</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bulcan.2018.05.016</ELocationID>            <Abstract>                <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Early phase therapeutic trials in oncology are being offered to an increasing number of patients. The objective of this study is to retrospectively evaluate the treatment efficacy and survival of patients included in early phase trials at the &quot;Institut de Cancérologie de l'Ouest&quot; (ICO), as well as the interest of the Royal Marsden Hospital (RMH) and PRONOPALL scores in this population.</AbstractText>                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">All patients with cancer screened or included for an early phase trial at ICO between January 2012 and December 2015 have been identified.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of 1312-screened patients, 710 were included in 115 trials (34 phase 1 trials). The absence of molecular anomaly was the main cause of inclusion failure (49.5%). The disease control rate was 90.9%, the median overall survival was 14.7 months (95% CI 12.7 to 16.4) and the median progression-free survival was 5.7 months (95% CI 5.5 to 6.6). The median overall survival was better for patients with good prognosis based on Royal Marsden Hospital score (16.6 months versus 6 months, P=0.0011) and PRONOPALL score (15.6 months versus 4.6 months, P&lt;0.001).</AbstractText>                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Our results are better than in the literature, mainly because of the high proportion of first-line treatments and the consideration of phase II trials. Patients with lung cancer particularly benefited from these treatments, in part because of the role of immunotherapy. The Royal Marsden Hospital score can guide the decision to include in early phase trials, whereas the PRONOPALL score is not enough efficient.</AbstractText>                <CopyrightInformation>Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Greilsamer</LastName>                    <ForeName>Charlotte</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Centre hospitalier départemental de Vendée, boulevard Stéphane-Moreau, 85000 La Roche-sur-Yon, France. Electronic address: charlotte.greilsamer@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Campion</LastName>                    <ForeName>Loïc</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Institut de cancérologie de l'Ouest site René-Gauducheau, boulevard du Professeur-Jacques-Monod, 44805 Saint-Herblain, France; CRCINA, Inserm UMR1232, 8, quai Moncousu, 44000 Nantes, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cabart</LastName>                    <ForeName>Mathilde</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Institut Bergonié, 229, cours de l'Argonne, 33000 Bordeaux, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gourmelon</LastName>                    <ForeName>Carole</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Institut de cancérologie de l'Ouest site René-Gauducheau, boulevard du Professeur-Jacques-Monod, 44805 Saint-Herblain, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Senellart</LastName>                    <ForeName>Hélène</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Institut de cancérologie de l'Ouest site René-Gauducheau, boulevard du Professeur-Jacques-Monod, 44805 Saint-Herblain, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bennouna</LastName>                    <ForeName>Jaafar</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>CHU de Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>fre</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D023361">Validation Studies</PublicationType>            </PublicationTypeList>            <VernacularTitle>Essais de phase précoce à l’Institut de cancérologie de l’Ouest : réponse au traitement et validation de scores pronostiques.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>06</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>France</Country>            <MedlineTA>Bull Cancer</MedlineTA>            <NlmUniqueID>0072416</NlmUniqueID>            <ISSNLinking>0007-4551</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017321" MajorTopicYN="Y">Clinical Trials, Phase I as Topic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017322" MajorTopicYN="Y">Clinical Trials, Phase II as Topic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Early phase trials</Keyword>            <Keyword MajorTopicYN="N">Essai thérapeutique de phase précoce</Keyword>            <Keyword MajorTopicYN="N">PRONOPALL score</Keyword>            <Keyword MajorTopicYN="N">Royal Marsden Hospital score</Keyword>            <Keyword MajorTopicYN="N">Score PRONOPALL</Keyword>            <Keyword MajorTopicYN="N">Score Royal Marsden Hospital</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>05</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>05</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30348261</ArticleId>            <ArticleId IdType="pii">S0007-4551(18)30189-9</ArticleId>            <ArticleId IdType="doi">10.1016/j.bulcan.2018.05.016</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>